These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36438823)

  • 1. X-box binding protein 1: A new metabolic mediator and drug target of metformin?
    Lou K; Sun P; Zhang C; Jiang Q; Pang S
    Front Pharmacol; 2022; 13():1013218. PubMed ID: 36438823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression.
    Zhu X; Yan H; Xia M; Chang X; Xu X; Wang L; Sun X; Lu Y; Bian H; Li X; Gao X
    Lipids Health Dis; 2018 May; 17(1):114. PubMed ID: 29759071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice.
    Liu X; Guo GL; Kong B; Hilburn DB; Hubchak SC; Park S; LeCuyer B; Hsieh A; Wang L; Fang D; Green RM
    Hepatology; 2018 Jul; 68(1):304-316. PubMed ID: 29377207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
    Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
    Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
    Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
    J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.
    Lin MJ; Dai W; Scott MJ; Li R; Zhang YQ; Yang Y; Chen LZ; Huang XS
    Oncotarget; 2017 Dec; 8(65):108802-108809. PubMed ID: 29312569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c.
    Wang L; Zhu X; Sun X; Yang X; Chang X; Xia M; Lu Y; Xia P; Yan H; Bian H; Gao X
    Lipids Health Dis; 2019 Nov; 18(1):197. PubMed ID: 31729980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
    Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
    Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice.
    Kim D; Lee JE; Jung YJ; Lee AS; Lee S; Park SK; Kim SH; Park BH; Kim W; Kang KP
    Int J Mol Med; 2013 Dec; 32(6):1293-302. PubMed ID: 24068196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice.
    Zamani-Garmsiri F; Ghasempour G; Aliabadi M; Hashemnia SMR; Emamgholipour S; Meshkani R
    IUBMB Life; 2021 Jan; 73(1):252-263. PubMed ID: 33326684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of gomisin N against hepatic steatosis through AMPK activation.
    Yun YR; Kim JH; Kim JH; Jung MH
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1095-1101. PubMed ID: 27914812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal acyl-CoA:diacylglycerol acyltransferase 2 overexpression enhances postprandial triglyceridemic response and exacerbates high fat diet-induced hepatic triacylglycerol storage.
    Uchida A; Slipchenko MN; Eustaquio T; Leary JF; Cheng JX; Buhman KK
    Biochim Biophys Acta; 2013 Aug; 1831(8):1377-85. PubMed ID: 23643496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct and maternal n-3 long-chain polyunsaturated fatty acid supplementation improved triglyceridemia and glycemia through the regulation of hepatic and muscle sphingolipid synthesis in offspring hamsters fed a high-fat diet.
    Kasbi-Chadli F; Ferchaud-Roucher V; Krempf M; Ouguerram K
    Eur J Nutr; 2016 Mar; 55(2):589-599. PubMed ID: 25787885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice.
    Liu Y; Millar JS; Cromley DA; Graham M; Crooke R; Billheimer JT; Rader DJ
    Biochim Biophys Acta; 2008 Mar; 1781(3):97-104. PubMed ID: 18252207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
    Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
    Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways.
    Yasmin T; Rahman MM; Khan F; Kabir F; Nahar K; Lasker S; Islam MD; Hossain MM; Hasan R; Rana S; Alam MA
    Biochem Biophys Rep; 2021 Dec; 28():101168. PubMed ID: 34825068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion.
    Butler JA; Hagen TM; Moreau R
    Arch Biochem Biophys; 2009 May; 485(1):63-71. PubMed ID: 19232511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive role for IRE1α-XBP1 signaling pathway in the insulin-mediated hepatic lipogenic program.
    Ning J; Hong T; Ward A; Pi J; Liu Z; Liu HY; Cao W
    Endocrinology; 2011 Jun; 152(6):2247-55. PubMed ID: 21447637
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Kim JH; Sim HA; Jung DY; Lim EY; Kim YT; Kim BJ; Jung MH
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.